Sullivan Mark
SEC CIK 1331843 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| DFTX | Definium Therapeutics, Inc. | CLO | 508.3K | — | $1.35M | 15 | 2023-04-13 | 2026-09-14 |
Most active insiders at DFTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Barrow Robert | CEO, Dir | — | $3.08M |
| 2 | Sullivan Mark | CLO | — | $1.04M |
| 3 | Karlin Daniel | Chief Medical Off | — | $748.9K |
| 4 | Roberts Brandi | CFO | — | $135.7K |
| 5 | Wiley Matthew T. | Chief Commercial Off | — | $129.1K |
| 6 | Adsett Roger | Dir | — | — |
| 7 | CRYSTAL ROGER | Dir | — | — |
| 8 | Bruhn Suzanne Louise | Dir | — | — |
| 9 | Krebs Andreas | Dir | — | — |
| 10 | Vallone Carol A | Dir | — | — |
Transactions 15
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 08:30 | 2026-09-14 | DFTX | Definium Therapeutics, Inc. | Sullivan Mark | CLO | A - Grant | $0.00 | +125.0K | 508.3K | +33% | $0 | |
| 2026-08-12 08:30 | 2026-08-12 | DFTX | Definium Therapeutics, Inc. | Sullivan Mark | CLO | A - Grant | $0.00 | +62.5K | 383.1K | +19% | $0 | |
| T | 2026-06-26 16:30 | 2026-06-25 | DFTX | Definium Therapeutics, Inc. | Sullivan Mark | CLO | S - Sale | $45.03 | -13.0K | 320.6K | -4% | -$585.8K |
| 2026-06-22 09:45 | 2026-06-22 | DFTX | Definium Therapeutics, Inc. | Sullivan Mark | CLO | A - Grant | $0.00 | +62.5K | 333.6K | +23% | $0 | |
| T | 2026-03-26 | 2026-03-25 | DFTX | Definium Therapeutics, Inc. | Sullivan Mark | CLO | S - Sale | $18.47 | -10.7K | 271.1K | -4% | -$197.7K |
| 2026-02-05 | 2026-02-03 | DFTX | Definium Therapeutics, Inc. | Sullivan Mark | CLO | A - Grant | $0.00 | +125.0K | 407.6K | +44% | $0 | |
| T | 2025-12-29 | 2025-12-26 | DFTX | Definium Therapeutics, Inc. | Sullivan Mark | CLO | S - Sale | $13.15 | -11.3K | 282.6K | -4% | -$148.3K |
| T | 2025-09-26 | 2025-09-25 | DFTX | Definium Therapeutics, Inc. | Sullivan Mark | CLO | S - Sale | $9.77 | -11.3K | 293.9K | -4% | -$110.2K |
| T | 2025-06-26 | 2025-06-25 | DFTX | Definium Therapeutics, Inc. | Sullivan Mark | CLO | S - Sale | $6.80 | -11.5K | 305.1K | -4% | -$78.1K |
| T | 2025-03-26 | 2025-03-25 | DFTX | Definium Therapeutics, Inc. | Sullivan Mark | CLO | S - Sale | $6.74 | -6,576 | 316.6K | -2% | -$44.3K |
| 2025-03-13 | 2025-03-12 | DFTX | Definium Therapeutics, Inc. | Sullivan Mark | CLO | A - Grant | $0.00 | +150.0K | 323.2K | +87% | $0 | |
| 2024-12-27 | 2024-12-26 | DFTX | Definium Therapeutics, Inc. | Sullivan Mark | CLO | S - Sale | $7.43 | -4,519 | 173.2K | -3% | -$33.6K | |
| T | 2024-09-25 | 2024-09-25 | DFTX | Definium Therapeutics, Inc. | Sullivan Mark | CLO | S - Sale | $5.98 | -4,430 | 177.7K | -2% | -$26.5K |
| T | 2024-06-25 | 2024-06-25 | DFTX | Definium Therapeutics, Inc. | Sullivan Mark | CLO | S - Sale | $7.22 | -17.9K | 182.1K | -9% | -$128.9K |
| 2023-04-14 | 2023-04-13 | DFTX | Definium Therapeutics, Inc. | Sullivan Mark | CLO | A - Grant | $0.00 | +200.0K | 200.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations